Building the Pharmaceutical Factory of the Future

Digitalization in the pharmaceutical industry is a pervasive and persistent phenomenon that rapidly changes how patients engage with pharma and purchase drugs. The pandemic has just accelerated the changes which already began before

Nitrosamines are potential mutagens and need to be controlled in human drug products. Recently, nitrosamine contamination of high-profile drugs has prompted numerous recalls, and increased regulatory assessments for marketed products.

Innovation continues to be a primary driver of value in pharmaceutical research. However, simultaneously, research budgets are coming under ever-increasing pressure. As a consequence, pharma is moving toward a so-called open research model, one that dispenses with recurrent fixed costs in favor of a more flexible and dynamic external “spend.” By adopting this model, pharma could tap into innovation outside their walls. In this webinar, case studies will be presented highlighting the value of such collaborations, while focusing on discovery campaigns that employ highly relevant functional assays.

The frontiers of data sciences and real-world data represent promising areas of innovation and possibility for life sciences and health-care organizations, especially within precision medicine. These areas are continuously evolving, and there are questions about how to navigate this complex and rapidly evolving set of resources, capabilities, and organizations. This webinar, in partnership with the Kraft Precision Medicine Accelerator at the Harvard Business School, aims to provide a landscape of the organizations working in real-world data and advanced analytics, including artificial intelligence and machine learning, and provide commentary on the recent changes to space. It will introduce attendees to the Kraft Precision Medicine Accelerator and teach them about real-world data analytics technologies and data assets that may help advance their research agendas, determine the subject of collaborations, or serve as an investment target.